Dual-Tracer PET Tumor Imaging

双示踪剂 PET 肿瘤成像

• 批准号: 10152095
• 负责人: Dan J Kadrmas
• 金额: $ 15万
• 依托单位: MULTIFUNCTIONAL IMAGING, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-12-01 至 2021-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10152095
• 关键词: Algorithms; Cardiac; Caring; Characteristics; Clinic; Clinical; Computer software; Coupled; Detection; Development; Devices; Diagnosis; Diagnostic; Diagnostic Imaging; Effectiveness; FDA approved; Feedback; Grant; Healthcare; Hour; Image; Imaging Techniques; Kinetics; Legal patent; Logistics; Magnetic Resonance Imaging; Malignant Neoplasms; Medical Device; Motion; Myocardial perfusion; Neuroendocrine Tumors; Oncology; Output; Patient imaging; Patients; Performance; Phase; Play; Positron-Emission Tomography; Protocols documentation; Radionuclide therapy; Rest; Role; Sampling; Scanning; Schedule; Signal Transduction; Small Business Innovation Research Grant; Staging; Stress; Techniques; Technology; Testing; Therapeutic Effect; Time; Tracer; Translating; Universities; Utah; Validation; Visit; base; cancer imaging; cost; design; dosimetry; effective therapy; fluorodeoxyglucose; fluorodeoxyglucose positron emission tomography; image guided; improved; meetings; neuroendocrine differentiation; new technology; predicting response; product development; prognostic; prospective; prototype; rapid technique; response; routine imaging; software development; targeted treatment; theranostics; tool; treatment strategy; tumor; uptake; validation studies; verification and validation; whole body imaging

Abstract Positron emission tomography (PET, including PET/CT and PET/MRI) with 18F-fluorodeoxyglucose (FDG) plays a key role in diagnosing and staging a wide variety of malignant tumors, assessing tumor grade, and evaluating response to therapy. The advent of other recently approved tracers, particularly those with theranostic partners, is opening a new era of imaging where the uptake of PET tracers can directly predict the effectiveness of certain targeted therapies. Such theranostic tracers image different aspects of tumor function than traditional diagnostic tracers (e.g. FDG), and they provide complementary images with different detection and staging performance across different levels of tumor differentiation and grade. The ability to routinely image multiple PET tracers in each patient would provide increased diagnostic performance, improved grading and staging information, and combine predictive theranostic imaging with the diagnostic workup. However, current technology requires that separate scans be performed for each tracer—usually on separate days—resulting in high cost, scheduling and logistical challenges, and undue burden on the patient. We propose to remove these obstacles by developing rapid dual-tracer PET tumor imaging techniques—providing accurate images of two PET tracers in a single scan, and making these techniques available for general clinical use. Multifunctional Imaging LLC (MFI) has previously developed a software medical device, mfiVerse™, which enables single-scan rest+stress myocardial perfusion PET imaging. This SBIR project will expand the software's capabilities to also support dual-tracer PET cancer imaging—a much broader set of applications that will serve many more clinical needs. We will first develop the capability to image FDG and Ga68 DOTATATE in a single, dual- tracer PET exam, which will provide improved imaging performance for both well- and poorly-differentiated neuroendocrine tumors, and simultaneously predict response to targeted radionuclide therapy with Lu177 DOTATATE. This Phase I project will establish a fully working prototype for dual-tracer PET tumor imaging, establish its initial operating performance, and set the stage for full product development and validation under a subsequent Phase II project. The device will also be expanded to support other tracer combinations in Phase II. Completion of this project will create a first-of-its-kind device for dual-tracer cancer PET imaging, enabling routine use of dual-tracer PET for a wide variety of cancer imaging indications.

抽象的 18F-氟脱氧葡萄糖正电子发射断层扫描（PET，包括 PET/CT 和 PET/MRI） (FDG) 在多种恶性肿瘤的诊断和分期、评估肿瘤方面发挥着关键作用 等级，并评估对治疗的反应。其他最近批准的示踪剂的出现，特别是 与治疗诊断合作伙伴一起，正在开启成像的新时代，PET 示踪剂的采用可以 直接预测某些靶向治疗的有效性。这种治疗诊断示踪剂图像不同 与传统的诊断示踪剂（例如 FDG）相比，它们在肿瘤功能方面的作用更强，并且它们提供了补充 不同肿瘤分化程度的图像具有不同的检测和分期性能 年级。对每位患者的多个 PET 示踪剂进行常规成像的能力将提供更多 诊断性能，改进的分级和分期信息，并结合预测治疗诊断 通过诊断检查进行成像。然而，当前的技术要求单独扫描 对每个跟踪器执行（通常在不同的日子）导致成本、调度和后勤成本高昂 挑战以及给患者带来的过度负担。我们建议通过快速发展来消除这些障碍 双示踪剂 PET 肿瘤成像技术——在一次扫描中提供两种 PET 示踪剂的准确图像， 并使这些技术可供一般临床使用。多功能成像有限责任公司 (MFI) 拥有 之前开发了一款软件医疗设备 mfiVerse™，可实现单扫描休息+压力 心肌灌注 PET 成像。该 SBIR 项目将扩展该软件的功能 支持双示踪剂 PET 癌症成像——一系列更广泛的应用，将服务于更多人 临床需要。我们将首先开发在单双通道中对 FDG 和 Ga68 DOTATATE 进行成像的能力 示踪剂 PET 检查，将为高分化和低分化的患者提供改进的成像性能 神经内分泌肿瘤，并同时预测 Lu177 对靶向放射性核素治疗的反应 多塔特。该一期项目将为双示踪剂 PET 肿瘤建立一个完全工作的原型 成像，建立其初始运营绩效，并为全面的产品开发和部署奠定基础 在随后的第二阶段项目中进行验证。该设备还将扩展以支持其他追踪器 第二阶段的组合。该项目的完成将创造出首个双追踪器设备 癌症 PET 成像，使双示踪剂 PET 能够常规用于各种癌症成像 迹象。